CAPR Stock Overview
A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Capricor Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.60 |
52 Week High | US$8.22 |
52 Week Low | US$2.68 |
Beta | 4.07 |
1 Month Change | 5.07% |
3 Month Change | 33.33% |
1 Year Change | 23.62% |
3 Year Change | 41.06% |
5 Year Change | 103.64% |
Change since IPO | -86.67% |
Recent News & Updates
Recent updates
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Capricor signs intellectual property license for COVID-19 serology test platform
Feb 01Capricor and Lonza tie up in DMD development
Jan 12Dosing underway in Capricor Therapeutics' mid-stage CAP-1002 study in COVID-19
Nov 24Shareholder Returns
CAPR | US Biotechs | US Market | |
---|---|---|---|
7D | -10.4% | -4.5% | -1.0% |
1Y | 23.6% | 4.6% | 25.2% |
Return vs Industry: CAPR exceeded the US Biotechs industry which returned 6.6% over the past year.
Return vs Market: CAPR underperformed the US Market which returned 25.4% over the past year.
Price Volatility
CAPR volatility | |
---|---|
CAPR Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 10.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CAPR's share price has been volatile over the past 3 months.
Volatility Over Time: CAPR's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 102 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc. Fundamentals Summary
CAPR fundamental statistics | |
---|---|
Market cap | US$194.05m |
Earnings (TTM) | -US$24.31m |
Revenue (TTM) | US$27.10m |
6.6x
P/S Ratio-7.3x
P/E RatioIs CAPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CAPR income statement (TTM) | |
---|---|
Revenue | US$27.10m |
Cost of Revenue | US$39.89m |
Gross Profit | -US$12.79m |
Other Expenses | US$11.52m |
Earnings | -US$24.31m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.76 |
Gross Margin | -47.20% |
Net Profit Margin | -89.72% |
Debt/Equity Ratio | 9.9% |
How did CAPR perform over the long term?
See historical performance and comparison